| |
We invite you to join us at the Fierce Medical Affairs Strategic Summit West. Join medical affairs, field medical, and medical communications teams to share best practices, gain actionable insights and crowdsource ideas to their unique challenges from their peers. Register now
|
|
Today's Big NewsJul 5, 2023 |
| By Nick Paul Taylor AstraZeneca and Daiichi Sankyo’s attempt to repeat the success of Enhertu has delivered its first phase 3 data. The antibody-drug conjugate improved progression-free survival in lung cancer patients but, with the partners yet to share numbers and “some” patients suffering fatal adverse events, shares in AstraZeneca fell almost 6% in early trading in London. |
|
|
|
By Fraiser Kansteiner In a deal that could be worth up to $1 billion, Massachusetts-based Moderna inked a memorandum of understanding, plus a land collaboration agreement, to research, develop and manufacture mRNA medicines in China. |
By Max Bayer Takeda and F-Star are tacking on another bispecific antibody deal worth $1 billion in potential milestones, marking the third time the two have partnered up in a year. |
By Andrea Park Just a few weeks after Abbott presented the successful results of a trial of its Aveir DR dual-chamber leadless pacemaker system—data that it said had been promptly submitted for regulatory review—the company has secured FDA approval for the technology. |
|
Wednesday, July 12, 2023 | 2pm ET/11am PT In this webinar, we will explore how critical it is for life sciences companies to use data to analyze the behavior of cancer at the individual level, uncover new targets and biomarkers for precision therapies, and increase the value of existing oncology drugs to new indications. Register now.
|
|
By Kevin Dunleavy With Pfizer set to launch its biosimilar version of AbbVie’s Humira, the company has expanded its partnership with Samsung Biologics, which will produce biosimilars for the pharma giant at its sprawling complex in South Korea. Samsung said on Monday that Pfizer had added to two biosimilar production agreements the companies had made earlier this year, making the combined total $897 million. |
By Annalee Armstrong Once one of the hottest vessels in the pharma fleet, SHP2 inhibitors are starting to retreat from the seas as AbbVie joins the list of companies ending work on a collaboration with Jacobio to develop therapies for the target. |
By Andrea Park Medtronic has identified a vulnerability that could potentially allow hackers to access the cardiac device data stored in its Paceart Optima data workflow systems. |
By Fraiser Kansteiner The FDA has rebuffed Amneal’s application for IPX203, an oral formulation of carbidopa/levodopa, which leverages a unique delivery formula in a bid to increase “on” time without troublesome dyskinesia. |
By Helen Floersh A new study from researchers at the University of California San Diego School of Medicine has found one potentially beneficial combo for pancreatic cancer: Mirati Therapeutics' KRAS inhibitor adagrasib, known as Krazati, and Boehringer Ingelheim’s ERBB gene inhibitor afatinib, trade name Gilotrif. |
By Angus Liu Another accelerated approval has run its course, with Roche giving up on a niche indication for cancer drug Gavreto. The move comes as the Swiss pharma giant prepares to terminate a collaboration with Blueprint Medicines. |
By Andrea Park Even as BD allots million of dollars toward expanding its presence in Ireland, the medtech giant is planning a simultaneous slimdown of one of its sites on the Emerald Isle. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss the American Diabetes Association's annual conference, plus a statement about transgender care, light therapy, and the rest of the week's headlines. |
|
|---|
|
|
|
Wednesday, July 12, 2023 | 11:00am ET / 8:00am PT Join us for this insightful discussion on how to unlock the full potential of liquid biopsy and be an integral part of the future of precision medicine. We’ll take a deep dive into the latest strategies and solutions designed to help overcome current challenges and empower researchers and clinicians with enhanced capabilities. Register now.
|
|
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookThis eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| eBookTake a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| |
|
